Recent non-core, business-related newsflow has proved highly beneficial to Medigene. The full and final transference of EndoTAG-1 rights to SynCore and the sale of its Catherex subsidiary to Amgen for $10.5m (40% to Medigene) tidies up its legacy pipeline and IP assets, while providing a decent revenue stream. Medigene’s core focus remains on its immuneoncology franchise, and we look forward to significant progress in 2016. Our rNPV-based valuation increases to €216m or €10.98 per share.
